Physician profile
Andrew M Smith
NPI 1164468955
$648,839.09
in general payments reported to CMS, 2019-2025
51 companies · $146K in 2025
The $146K reported for 2025 was more than what 99% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67K · 2020: $29K · 2021: $80K · 2022: $114K · 2023: $60K · 2024: $152K · 2025: $146K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $226K · Consulting Fee: $84K · Travel and Lodging: $32K · Food and Beverage: $16K · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $226,362.50 |
| Consulting Fee | $84,003.94 |
| Travel and Lodging | $31,685.34 |
| Food and Beverage | $15,819.70 |
| Education | $139.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $219,931.24 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Takeda Pharmaceuticals U.S.A., INC. | $145,637.02 | 2020-2025 | Takhzyro, Cinryze, Eohilia |
| Pharming Healthcare, INC. | $77,683.15 | 2019-2025 | Ruconest |
| Biocryst US Sales Co., LLC | $69,609.01 | 2021-2025 | Orladeyo |
| Optinose US, INC. | $39,226.97 | 2019-2025 | |
| Shire North American Group INC | $27,449.61 | 2019 | |
| Csl Behring | $15,206.20 | 2019-2025 | Andembry, Hizentra, Haegarda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14,467.54 | 2019-2023 | Spiriva |
| Amgen INC. | $6,261.95 | 2021-2025 | Tezspire, Actimmune |
| Genzyme Corporation | $4,862.79 | 2019-2025 | |
| Ionis Pharmaceuticals, INC. | $4,336.21 | 2025 | Dawnzera |
| Biocryst Pharmaceuticals, INC. | $3,842.61 | 2019-2024 | |
| Regeneron Pharmaceuticals, INC. | $2,890.57 | 2022-2025 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $2,785.62 | 2019-2023 | Airduo Digihaler |
| Blueprint Medicines Corporation | $2,705.34 | 2022-2025 | Ayvakit |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $2,120.00 | 2024 | Vtama |
| Sanofi US Services INC. | $1,952.00 | 2024 | |
| Abbvie INC. | $1,494.19 | 2022-2024 | Rinvoq |
| Novartis Pharmaceuticals Corporation | $1,466.10 | 2019-2025 | |
| Glaxosmithkline, LLC. | $783.61 | 2019-2025 | Nucala, Trelegy Ellipta |
| Grifols USA, LLC | $586.41 | 2020-2025 | Xembify, Prolastin-C Liquid |
| Pfizer INC. | $484.09 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $480.59 | 2019-2025 | Dupixent |
| Kaleo, INC. | $387.46 | 2019-2024 | Auvi-Q |
| Genentech USA, INC. | $379.48 | 2021-2025 | Xolair |
| Adma Biomanufacturing LLC | $276.87 | 2021-2025 | |
| Mylan Specialty L.P. | $226.17 | 2021-2024 | Yupelri |
| Ars Pharmaceuticals Operations, INC. | $149.76 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $142.36 | 2022-2025 | |
| Cycle Pharmaceuticals INC | $112.47 | 2024-2025 | Sajazir |
| Incyte Corporation | $101.97 | 2025 | Opzelura |
| Genentech, INC. | $88.61 | 2024 | Xolair |
| Tersera Therapeutics LLC | $75.98 | 2025 | Quzyttir |
| Bio Products Laboratory USA, INC. | $73.96 | 2021-2022 | |
| Octapharma USA, INC. | $70.85 | 2021-2022 | |
| Organon LLC | $66.25 | 2025 | |
| Lilly USA, LLC | $63.85 | 2024-2025 | Ebglyss |
| Circassia INC. | $60.56 | 2019-2021 | |
| Leo Pharma INC. | $55.78 | 2024-2025 | Adbry |
| Sunovion Pharmaceuticals INC. | $47.65 | 2019 | |
| Aimmune Therapeutics, INC. | $37.75 | 2022 | |
| Azurity Pharmaceuticals, INC. | $20.70 | 2025 | Alvesco |
| Insmed, INC. | $20.69 | 2025 | Brinsupri, Arikayce |
| Verona Pharma, INC. | $20.25 | 2025 | Ohtuvayre |
| Hikma Pharmaceuticals USA | $19.84 | 2023 | Ryaltris |
| Paratek Pharmaceuticals, INC. | $16.58 | 2025 | Xhance |
| Angiodynamics, INC. | $16.31 | 2025 | Auryon Laser System 100-120 Vac |
| Merck Sharp & Dohme LLC | $15.42 | 2021 | |
| Kedrion Biopharma INC. | $15.21 | 2021 | |
| Lucid Diagnostics INC. | $13.49 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.